Damora Therapeutics (DMRA) Non Operating Income (2019 - 2026)
Damora Therapeutics (DMRA) reported Non Operating Income of $3.1 million for Q1 2026, up 4414.71% on a YoY basis from $68000.0 in Q1 2025, and up 205.78% quarter-over-quarter from $1.0 million in Q4 2025.
Damora Therapeutics (DMRA) Non Operating Income (2019 - 2026) Analysis & Trends
Damora Therapeutics has reported Non Operating Income for 8 years, with the latest figure at $3.1 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 4414.71% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $4.1 million (up 513.36% YoY), and the FY2025 full-year result was $1.1 million, up 25.64% from the prior year.
- Non Operating Income for Q1 2026 stood at $3.1 million, up from $1.0 million in the prior quarter.
- The five-year high for Non Operating Income was $3.1 million in Q1 2026, with the low at -$544000.0 in Q4 2022.
- Historically, Non Operating Income has averaged $362000.0 across 5 years, with a median of $234000.0 in 2022.
- Annual changes were most pronounced in 2022 — Non Operating Income slumped 1022.03% — and 2023, when it jumped 49700.0%.
- Damora Therapeutics' Non Operating Income stood at -$544000.0 in 2022, then soared by 136.03% to $196000.0 in 2023, then jumped by 80.1% to $353000.0 in 2024, then surged by 184.42% to $1.0 million in 2025, then soared by 205.78% to $3.1 million in 2026.
- The last three Non Operating Income figures came in at $3.1 million (Q1 2026), $1.0 million (Q4 2025), and $23000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Damora Therapeutics | 731.26 Mn | 528.86 Mn | - | 3.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.07 Mn |
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 23,000.00 |
| Jun 30, 2025 | -12,000.00 |
| Mar 31, 2025 | 68,000.00 |
| Dec 31, 2024 | 353,000.00 |
| Sep 30, 2024 | -36,000.00 |
| Jun 30, 2024 | 281,000.00 |
| Mar 31, 2024 | 264,000.00 |
| Dec 31, 2023 | 196,000.00 |
| Sep 30, 2023 | 447,000.00 |
| Jun 30, 2023 | 415,000.00 |
| Mar 31, 2023 | 498,000.00 |
| Dec 31, 2022 | -544,000.00 |
| Sep 30, 2022 | -108,000.00 |
| Jun 30, 2022 | 234,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Dec 31, 2021 | 59,000.00 |
| Sep 30, 2021 | 243,000.00 |
| Jun 30, 2021 | -34,000.00 |